KMKenny Malpartida-Cardenas

Kenny Malpartida-Cardenas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenny Malpartida-Cardenas has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stoichiometric Encoding of Amplification Kinetics Enables High-Level Multiplexing in Single-Channel TaqMan Real-Time PCR

    by Louis Kreitmann, Kenny Malpartida-Cardenas, Ye Mao, Karolina Sobala, Zexuan Zhao, San Chun Hin, Anirudhha Hazarika, Ke Xu, Luca Miglietta, Zara Breese, et al.

    Multiplexing in TaqMan real-time PCR (qPCR) is limited to four-six targets per reaction by fluorophore spectral overlap. Amplification curve analysis (ACA) can discriminate several targets within one fluorescence channel from amplification curves (AC) kinetic features, but has been confined mainly to digital qPCR (dqPCR) and is sensitive to domain shifts between instruments and specimen types. Here, we co-design biochemical encoding of target-specific information into ACs and their computational decoding to achieve single-channel 8-plex TaqMan qPCR on a standard thermocycler. Using asymmetric PCR, we show that forward primer, reverse primer and probe concentrations act as a programmable encoding mechanism, generating a 27-condition design space of reproducible non-canonical ACs, conserved from digital to bulk qPCR. Applying this stoichiometric encoding to an 8-plex central nervous system pathogens panel increased inter-target separability, raising the mean silhouette score from 0.329 to 0.711. To decode ACs without labelled target-domain bulk qPCR data, we pretrained a transformer encoder by self-supervised learning on more than 170,000 unlabelled dqPCR curves and aligned source and target domains using conditional domain adversarial training. On contrived clinical specimens, the framework classified a canonical 7-plex respiratory virus panel with 83.6% accuracy (versus 67.7% for a supervised baseline) and the encoded 8-plex panel with 89.8% accuracy. Furthermore, stoichiometric encoding enabled resolution of double- and triple-target co-amplification events with 98.7% accuracy in controlled dqPCR experiments. This approach expands the information capacity of existing qPCR instrumentation without new hardware, fluorophores or oligonucleotides, offering a low-cost route to syndromic molecular diagnostics.

  • Open Access

    AI-Driven Workflow for Automated Colorimetric Isothermal Amplification for Robust Pathogen Detection on Portable Devices

    by Ke Xu, Matthew L. Cavuto, Kenny Malpartida-Cardenas, Marcus Pond, Dimbintsoa Rakotomalala Robinson, Francois Kiemde, Bernard Hernandez, Shiranee Sriskandan, Umberto D’ALessandro, Annette Erhart, et al.

    Point-of-Care (POC) portable devices have shown significant potential for rapid pathogen identification in limited-resource settings. Colorimetric LAMP (cLAMP)-based POC nucleic acid testing is particularly promising due to its speed, sensitivity, and simple visual readout. However, there is a need for a universal, automated color detection method to improve ease of use and reduce readout subjectivity using portable devices. We proposed an AI-driven workflow for automatic detection of multiple pathogens using cLAMP in a multitube strip format. Following sample extraction, reagent rehydration, and reaction incubation, the cLAMP panel was photographed with a portable device. The algorithm performed: (1) image preprocessing to locate tubes; (2) segmentation and cleaning to extract the liquid-filled region using deep learning and Otsu's binarization, followed by pixel cleaning; (3) empty tube and invalid control checks; and (4) color detection using relative Maximum Mean Discrepancy (MMD; a nonparametric statistical distance between the hue distributions of two tube images) to identify samples. The AI workflow was evaluated on 1,636 photos from 527 tests for the differential diagnosis of three panels, for skin-tropic viruses, respiratory viral pathogens, and malaria parasites, under various lighting conditions in POC environments. The AI workflow was compared to expert-adjudicated human visual readouts as the reference standard. Rejection of invalid photos, defined as panels containing empty tubes or failed controls, achieved 98.94%, 98.29%, and 96.68% accuracy (95% CI 97.83−99.57%, 96.97−99.15%, 94.13−98.33%) for the three panels, respectively. Misclassified images were caused by human mistakes or extreme lighting conditions. Color identification on accepted images achieved 99.97%, 100%, and 99.69% accuracy (95% CI 99.82−100% for Data set 1 and 98.27−99.99% for Data set 3; one-sided 95% lower bound 99.90% for Data set 2). This study demonstrates a reliable automatic color readout workflow for cLAMP-based nucleic acid detection, showing potential for integration into POC testing apps for cloud-based use.

  • Open Access

    Lyophilised colourimetric LAMP for visual readout with dual colour indicators

    by Kenny Malpartida-Cardenas, Oliver W. Stringer, Matthew L. Cavuto, Alison Holmes, Jesus Rodriguez-Manzano

    Development and optimisation of ready-to-use lyophilised colourimetric LAMP (lyo-cLAMP) integrating pH and metal indicators, only requiring addition of extracted nucleic acids. Compatible with any LAMP assay, it enables adaptation to any target.


  • Open Access

    Molecular characterisation of malaria and glucose-6-phosphate dehydrogenase deficiency in conflict-affected zones of central and eastern Sudan

    by Waleed Jebreel, Muzamil Abdel Hamid, Sayed Mustafa, Fahad Awad, Martin Chamai, Kenny Malpartida-Cardenas, Linda Amoah, Jesus Rodriguez-Manzano, Aubrey J. Cunnington, Abdelrahim Mohamed

    Background Malaria causes high morbidity and mortality in Sudan. Conflict and displacement have disrupted control efforts, likely increasing disease transmission. This study explored malaria epidemiology, parasite distribution, hematological changes, and the distribution of Glucose-6-Phosphate Dehydrogenase (G6PD) genotypes in conflict-affected zones hosting internally displaced populations (IDPs). Methods This cross-sectional study was conducted between 2023 and 2024, enrolling 717 patients with clinical symptoms suggestive of malaria in Kosti (Central Sudan, n = 252) and Kassala (Eastern Sudan, n = 465). Malaria infection was confirmed by light microscopy and species-specific real-time PCR targeting the 18S rRNA gene. Hematological indices were analyzed on automated analyzers, and PCR-RFLP was used to determine G6PD genotypes. Results PCR-confirmed malaria prevalence was 62.6% in Kassala and 52% in Kosti. P. vivax and P. falciparum were co-endemic in Kassala (66.2% and 46.2%), with 12.4% mixed infections and 24% sub-microscopic P. vivax infections. P. falciparum was most common in Kosti (97.7%). P. vivax infections often were afebrile (74%) and associated with thrombocytopenia (p = 0.001). Significant regional variation in G6PD genotypes was found (p < 0.001): the A- variant was detected in males from Kosti (7.4%) but not in males from Kassala. Kosti females showed a female-specific deficiency: 15.8% of males carried the A variant, while 8.3%, 2.5%, and 1.3% of females were heterozygous for A⁻ , homozygous for A , and homozygous or compound for A⁻ , respectively. In Kassala, 2.7% of males had the A variant, and 1.6% and 3% of females were BA⁻ and AA , respectively. Malaria prevalence did not vary significantly between IDPs and residents. Conclusions This study found a high prevalence of P. vivax in eastern Sudan, with co-endemicity of P. falciparum and a significant number of sub-microscopic infections. It revealed regional heterogeneity in G6PD deficiency, with the A⁻ variant only found among males from Kosti, central Sudan. Notably, this study adds to the scarce molecular data on G6PD deficiency in Sudan by documenting the presence of the G6PD A⁻ allele and the A⁻A⁻ genotype, confirming the sub-Saharan African A⁻ allele in the population.

  • Open Access

    Lyophilised colourimetric LAMP for visual readout with dual colour indicators

    by Kenny Malpartida-Cardenas, Oliver W. Stringer, Matthew L. Cavuto, Alison Holmes, Jesus Rodriguez-Manzano

    Loop-mediated isothermal amplification (LAMP) is increasingly recognised as a practical alternative to PCR for pathogen detection due to its shorter turnaround time, constant operating temperature, and compatibility with a wide range of detection methods. Colourimetric LAMP has gained popularity due to its potential for instrument-free readout, making it attractive for molecular diagnostics in low-resource settings. Despite these advantages, the widespread adoption of colourimetric LAMP at the point-of-care remains limited due to the need for cold-chain storage and trained personnel. This work introduces the development and optimisation of ready-to-use lyophilised colourimetric LAMP (lyo-cLAMP) that does not require cold-chain, additional reagents, or manual intervention beyond the addition of extracted nucleic acids from a sample, which indicates the presence of a target of interest by colour change after amplification. A variety of pH and metal indicators were screened and combined to evaluate their synergy, identifying four combinations with high discrimination between positive and negative amplification. The performance of lyo-cLAMP was assessed with synthetic SARS-CoV-2 RNA, comparing it to the liquid format and achieving the same limit-of-detection. Lastly, the translation of lyo-cLAMP to diagnostic applications was demonstrated by screening clinical positive SARS-CoV-2 samples, achieving high accuracy. The developed lyo-cLAMP is compatible with any LAMP assay, allowing for rapid adaptation to new targets, which is particularly valuable in outbreak scenarios.

  • Open Access

    Sensitive near point-of-care detection of asymptomatic and submicroscopic Plasmodium falciparum infections in African endemic countries

    by Dimbintsoa Rakotomalala Robinson, Ivana Pennisi, Matthew L. Cavuto, Francois Kiemde, Martin Chamai, Diane Yirgnur Some, Elliot Quigley, Kenny Malpartida-Cardenas, Mamadou O. Ndiath, Simon Correa, et al.

    Limited diagnostic capacity for detecting asymptomatic malaria infections with low parasite densities hinders elimination efforts in Africa. Here, we adapt a near point-of-care, LAMP-based diagnostic platform for malaria diagnosis using capillary blood. This Pan/Pf detection method meets the Malaria Eradication Research Agenda (malERA) criteria for community-level screening, with a limit of detection of 0.6 parasites/μL and a sample-to-result time under 45 minutes. We evaluate its performance on 672 capillary blood samples collected at the community level in The Gambia and Burkina Faso, including 146 Plasmodium falciparum positives confirmed by qPCR. The diagnostic platform achieved 95.2% sensitivity (95% CI: 90.4–98.1) and 96.8% specificity (95% CI: 94.9–98.0). It also detected 94.9% (130/137) of asymptomatic infections and 95.3% (41/43) of submicroscopic cases (<16 parasites/μL), outperforming expert microscopy (70.1% and 0%) and rapid diagnostic tests (49.6% and 4.7%). This field-deployable molecular diagnostic method offers a sensitive, scalable solution to support test-and-treat strategies for malaria elimination across Africa.


  • Open Access

    High-Sensitivity Near Point-of-Care Detection of Asymptomatic and Sub-microscopic Plasmodium Infections in African Endemic Countries

    by Dimbintsoa Rakotomalala Robinson, Ivana Pennisi, Matthew L. Cavuto, Francois Kiemde, Martin Chamai, Diane Yrgnur Some, Elliot Quigley, Kenny Malpartida Cardenas, Mamadou Ousmane Ndiath, Simon Correa, et al.

    The limited diagnostic capacity to detect asymptomatic individuals with low parasite densities continues to hinder malaria elimination efforts across Africa. We adapted a near point-of-care LAMP-based diagnostic platform, originally designed for viral detection in respiratory and skin lesion specimens, for malaria diagnosis using capillary blood. The resulting Pan /Pf malaria test meets the Malaria Eradication Research Agenda (malERA) essential criteria for community-level malaria screening, with an analytical limit-of-detection of 0.6 parasites/μL and a sample-to-result turnaround time under 45 minutes. We evaluated the test using 672 capillary blood samples obtained via finger pricks from individuals enrolled at the community level in The Gambia and Burkina Faso, including 146 positives for P. falciparum confirmed by dried blood spot qPCR. The test achieved a sensitivity of 95.2% [95% CI: 90.4-98.1] and specificity of 96.8% [95% CI: 94.9-98.0]. It also detected 94.9% (130/137) of asymptomatic malaria infections and 95.3% (41/43) of sub-microscopic cases (<16 parasites/µL), outperforming expert light microscopy, which detected 70.1% (96/137) and 0% (0/43), and rapid diagnostic tests, which detected 49.6% (68/137) and 4.7% (2/43), respectively. This field molecular method represents a sensitive and scalable diagnostic solution with the potential to support test-and-treat strategies for malaria elimination across Africa.


  • Top Cited Papers
    Open Access

    Portable molecular diagnostic platform for rapid point-of-care detection of mpox and other diseases

    by Matthew L. Cavuto, Kenny Malpartida-Cardenas, Ivana Pennisi, Marcus J. Pond, Sohail Mirza, Nicolas Moser, Mark Comer, Isobel Stokes, Lucy Eke, Sian Lant, et al.

    The World Health Organization’s designation of mpox as a public health emergency of international concern in August 2024 underscores the urgent need for effective diagnostic solutions to combat this escalating threat. The rapid global spread of clade II mpox, coupled with the sustained human-to-human transmission of the more virulent clade I mpox in the Democratic Republic of Congo, highlights a critical gap in point-of-care diagnostics for this emergent disease. In response, we developed Dragonfly, a portable molecular diagnostic platform for point-of-care use that integrates power-free nucleic acid extraction (<5 minutes) with lyophilised colourimetric LAMP chemistry. The platform demonstrated an analytical limit-of-detection of 100 genome copies per reaction for monkeypox virus, effectively distinguishing it from other orthopoxviruses, herpes simplex virus, and varicella-zoster virus. Clinical validation on 164 samples, including 51 mpox-positive cases, yielded 96.1% sensitivity and 100% specificity for orthopoxviruses, and 94.1% sensitivity and 100% specificity for monkeypox virus. Here, we present a rapid, accessible, and robust point-of-care diagnostic solution for mpox, suitable for both low- and high-resource settings, addressing the global resurgence of orthopoxviruses in the context of declining smallpox immunity.


  • Open Access

    Dragonfly: A Portable Molecular Diagnostic Platform for Rapid Point-of-Care Detection of Mpox and Other Diseases

    by Jesus Rodriguez Manzano, Matthew Cavuto, Kenny Malpartida Cardenas, Ivana Pennisi, Marcus Pond, Sohail Mirza, Nicholas Moser, Mark Comer, Isobel Stokes, Lucy Eke, et al.

    The explosive global spread of Clade II mpox in humans and sustained human-to-human transmission of the more virulent Clade I mpox in the Democratic Republic of Congo highlight both the current lack of, and critical need for, point-of-care diagnostics to address the spread of this emergent disease. A novel point-of-care molecular diagnostic platform, Dragonfly, was developed that integrates power-free nucleic acid extraction (< 5 minutes) and lyophilized colorimetric LAMP chemistry. The platform achieved an analytical limit-of-detection of 50 genome copies/reaction for monkeypox virus, distinguishing it from other orthopoxviruses, herpes simplex virus and varizella zoster virus. Clinical validation using 164 samples, including 51 mpox positives, demonstrated 96.1% sensitivity and 100% specificity for orthopoxviruses, and 94.1% sensitivity and 100% specificity for monkeypox virus. Our platform provides a rapid, accessible and robust point-of-care solution for monitoring mpox in both low and high resource settings amidst declining worldwide smallpox immunity, with broad potential to the wider field of infectious disease diagnosis as a whole.


  • Open Access

    Rapid, Portable, and Electricity-free Sample Extraction Method for Enhanced Molecular Diagnostics in Resource-Limited Settings

    by Ivana Pennisi, Matthew L. Cavuto, Luca Miglietta, Kenny Malpartida-Cardenas, Oliver W. Stringer, Katerina-Theresa Mantikas, Ruth Reid, Rebecca Frise, Nicolas Moser, Paul Randell, et al.

    The COVID-19 pandemic has highlighted the need for rapid and reliable diagnostics that are accessible in resource-limited settings. To address this pressing issue, we have developed a rapid, portable, and electricity-free method for extracting nucleic acids from respiratory swabs (i.e. nasal, nasopharyngeal and buccal swabs), successfully demonstrating its effectiveness for the detection of SARS-CoV-2 in residual clinical specimens. Unlike traditional approaches, our solution eliminates the need for micropipettes or electrical equipment, making it user-friendly and requiring little to no training. Our method builds upon the principles of magnetic bead extraction and revolves around a low-cost plastic magnetic lid, called SmartLid, in combination with a simple disposable kit containing all required reagents conveniently prealiquoted. Here, we clinically validated the SmartLid sample preparation method in comparison to the gold standard QIAamp Viral RNA Mini Kit from QIAGEN, using 406 clinical isolates, including 161 SARS-CoV-2 positives, using the SARS-CoV-2 RT-qPCR assays developed by the US Centers for Disease Control and Prevention (CDC). The SmartLid method showed an overall sensitivity of 95.03% (95% CI: 90.44-97.83%) and a specificity of 99.59% (95% CI: 97.76-99.99%), with a positive agreement of 97.79% (95% CI: 95.84-98.98%) when compared to QIAGEN's column-based extraction method. There are clear benefits to using the SmartLid sample preparation kit: it enables swift extraction of viral nucleic acids, taking less than 5 min, without sacrificing significant accuracy when compared to more expensive and time-consuming alternatives currently available on the market. Moreover, its simplicity makes it particularly well-suited for the point-of-care where rapid results and portability are crucial. By providing an efficient and accessible means of nucleic acid extraction, our approach aims to introduce a step-change in diagnostic capabilities for resource-limited settings.